WBI Investments LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

WBI Investments LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 128,801 shares of the biopharmaceutical company's stock, valued at approximately $3,417,000. Pfizer comprises approximately 0.9% of WBI Investments LLC's holdings, making the stock its 22nd largest position.

A number of other hedge funds have also recently made changes to their positions in the business. Rialto Wealth Management LLC bought a new position in shares of Pfizer in the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. purchased a new stake in Pfizer in the 4th quarter valued at $27,000. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer during the 4th quarter valued at $28,000. Noble Wealth Management PBC purchased a new position in Pfizer during the 4th quarter worth $31,000. Finally, Bernard Wealth Management Corp. bought a new stake in shares of Pfizer in the 4th quarter worth $33,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 1.0%

Shares of NYSE:PFE opened at $22.83 on Monday. The company has a market cap of $129.77 billion, a PE ratio of 16.19, a P/E/G ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The stock's 50-day moving average is $23.65 and its 200 day moving average is $25.32. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter last year, the business posted $0.82 EPS. The firm's revenue for the quarter was down 7.8% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.54%. Pfizer's dividend payout ratio is presently 124.64%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on PFE shares. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Finally, Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.